I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER OF PATENTS, WASHINGTON, D.C. 20231, ON 27 February 1998

AGENT/ATTORNEX FOR APPLICANT

Attorney Docket No. P50186-2

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Holmes, et al.

27 February 1998

RECEIVED

Serial No.:

08/612,929

Group Art Unit No.: 1806

Filed:

June 7, 1995

Examiner:

M. Navarro

MATRIX CUSTOMER

For:

Recombinant IL4 Antibodies Useful in Treatment of IL4 Mediated Disorders

**Assistant Commissioner of Patents** Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R.\§1.97(c)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

The references cited herein are listed on the enclosed PTO Form 1449. Copies 1998 RALEXAND 00000105 DAM:192570 of each are enclosed.

> This statement is being filed under the provisions of 37 CFR §1.97(c), before the mailing date of a Final Office action or before the mailing date of a Notice of Allowance, along with authorization to charge the \$240.00 fee specified in 37 CFR §1.17(p) to the Deposit Account No. 19-2570.

Serial No.: 08/612,929 Group Art Unit No.: 1806

Please charge any additional fees under 37 CFR §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to the indicated Deposit Account.

Respectfully submitted,

Alissa M. Eagle

Attorney for Applicants Registration No. 37,126

SMITHKLINE BEECHAM CORPORATION Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 Phone (610) 270-5364 Facsimile (610) 270-5090 n:\erg\apps\P50186-2\idsltr